Michael Rivner
Professor
Michael Rivner
Professor
Academic Appointment(s)
Medical College of Georgia
Department of Neurology
Emeritus Faculty
Medical College of Georgia
Department of Neuroscience and Regenerative Medicine
Administration
Department of The Graduate School
Bio
I am a specialist in Neuromuscular diseases. I established and run the ALS clinic. I have research grants in Myasthenia Gravis and ALS. I run the EMG lab at Wellstar MCG-Health. I also have an interest in botulinum toxins.
- MRIVNER@augusta.edu
- (706) 721-2681
- (706) 721-8701
- BP 4390
Education
-
MD, Medicine Emory University, 1978
-
BA, Psychology, General Duke University, 1972
-
BA, Zoology/Animal Biology Duke University, 1972
Certifications
-
DEA DEA, 2025
-
PHY GA Composite Medical Brd, 2025
-
South Carolina 1980
-
BLS American Heart Association, 2024
-
PHY GA Composite Medical Brd, 1979
-
BLS 2014
Awards & Honors
-
Lifetime Acheivement Award--2023 Augusta University, 2023
-
Outstanding Teacher of the Year 2015-2016 Department of Neurology, 2016
-
Clinical Science Teaching Award 2011 Medical College of Georgia, 2011
-
Neurology Department Outstanding Teacher of the year 2010 Neurology Department, 2010
-
Neurology Department Outstanding Teacher of the Year Neurology Department, 2006
Courses Taught Most Recent Academic Year
-
NEUR 5000
Basic Clkshp in Neurology
-
RNEU 5004
Clinical Neurophysiology
-
NEUR 5022
EMG Elective
-
RNEU 5000
Neurology
-
NEUR 5020
Neuromuscular Disease
Teaching Interests
EMG, ALS, Myasthenia Gravis, Neuromuscular diseases, botulinum toxin
Scholarship
Selected Recent Publications
- BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial, 2026
Journal Article, Academic Journal - Multicenter Expanded Access Protocol for Research Through Access to Trehalose in People With Amyotrophic Lateral Sclerosis, 2025
Journal Article, Academic Journal - Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial, 2025
Journal Article, Academic Journal - Efficacy and Safety of Autologous BCMA-directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis: Results from a Phase 2b Randomized Placebo-controlled Trial (S34.002), 2025
Journal Article, Academic Journal - Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial., 2025
Journal Article, Academic Journal
Research Interests
EMG
ALS
Myasthenia Gravis
Botulinum Toxins
Department Service
-
EMG Lab 1983 - Present
Role: Other
Professional Service
-
ALS Clinic 2007 - 2018
Role: Director
-
EMG Lab 1983 - 2018
Role: Director